Cargando…

Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity

OBJECTIVE: To investigate the influence of heterogeneity in disease progression for detecting treatment effects in Alzheimer disease (AD) trials, using a simulation study. METHODS: Individuals with an abnormal amyloid PET scan, diagnosis of mild cognitive impairment or dementia, baseline Mini-Mental...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jutten, Roos J., Sikkes, Sietske A.M., Van der Flier, Wiesje M., Scheltens, Philip, Visser, Pieter Jelle, Tijms, Betty M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205463/ https://www.ncbi.nlm.nih.gov/pubmed/34550903 http://dx.doi.org/10.1212/WNL.0000000000012022

Ejemplares similares

Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease
por: Dicks, Ellen, et al.
Publicado: (2019)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults
por: ten Kate, Mara, et al.
Publicado: (2018)

Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
por: Tijms, Betty M., et al.
Publicado: (2018)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study
por: Jutten, Roos J., et al.
Publicado: (2017)

Gray matter T1‐w/T2‐w ratios are higher in Alzheimer's disease
por: Pelkmans, Wiesje, et al.
Publicado: (2019)

Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire
por: Jutten, Roos J., et al.
Publicado: (2017)

Grey matter network trajectories across the Alzheimer’s disease continuum and relation to cognition
por: Dicks, Ellen, et al.
Publicado: (2020)

Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
por: Duits, Flora H., et al.
Publicado: (2021)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
por: Vromen, Eleonora M., et al.
Publicado: (2022)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

Everyday Functioning in a Community-Based Volunteer Population: Differences Between Participant- and Study Partner-Report
por: Verrijp, Merike, et al.
Publicado: (2022)

The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design
por: Bertens, Daniela, et al.
Publicado: (2017)

Amyloid‐β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest‐old
por: Pelkmans, Wiesje, et al.
Publicado: (2021)

Dutch Brain Research Registry for study participant recruitment: Design and first results
por: Zwan, Marissa D., et al.
Publicado: (2021)

Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum
por: Dubbelman, Mark A., et al.
Publicado: (2020)

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal
por: Vermunt, Lisa, et al.
Publicado: (2019)

Single-Subject Grey Matter Graphs in Alzheimer's Disease
por: Tijms, Betty M., et al.
Publicado: (2013)

Determining the Minimal Important Change of Everyday Functioning in Dementia: Pursuing Clinical Meaningfulness
por: Dubbelman, Mark A., et al.
Publicado: (2022)

Correction: Single-Subject Grey Matter Graphs in Alzheimer's Disease
por: Tijms, Betty M., et al.
Publicado: (2013)

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
por: Bertens, Daniela, et al.
Publicado: (2017)

A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility
por: Jutten, Roos J., et al.
Publicado: (2017)

The Cognitive‐Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch‐Cog study cohort
por: Jutten, Roos J., et al.
Publicado: (2020)

Experiences of and recommendations on clinical trial design in Alzheimer’s disease from the participant’s point of view: a mixed-methods study in two clinical trial centers in the Netherlands
por: Ottenhoff, Lois, et al.
Publicado: (2023)

Cross-cultural adaptation and validation of the Amsterdam Instrumental Activities of Daily Living questionnaire short version German for Switzerland
por: Bruderer-Hofstetter, Marina, et al.
Publicado: (2020)

Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline
por: Verfaillie, Sander C.J., et al.
Publicado: (2016)

Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimer’s Disease
por: Adriaanse, Sofie M., et al.
Publicado: (2014)

Web-Based Multidomain Lifestyle Programs for Brain Health: Comprehensive Overview and Meta-Analysis
por: Wesselman, Linda MP, et al.
Publicado: (2019)

Changes in Brain-Health Related Modifiable Risk Factors in Older Adults After One Year of COVID-19-Restrictions
por: Waterink, Lisa, et al.
Publicado: (2022)

Amsterdam Dementia Cohort: Performing Research to Optimize Care
por: van der Flier, Wiesje M., et al.
Publicado: (2018)

Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage
por: Poil, Simon-Shlomo, et al.
Publicado: (2013)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Computer-assisted prediction of clinical progression in the earliest stages of AD
por: Rhodius-Meester, Hanneke F.M., et al.
Publicado: (2018)

Neuropsychological Test Performance of Cognitively Healthy Centenarians: Normative Data From the Dutch 100‐Plus Study
por: Beker, Nina, et al.
Publicado: (2018)

Exercise and Early-Onset Alzheimer's Disease: Theoretical Considerations
por: Hooghiemstra, Astrid M., et al.
Publicado: (2012)

LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project
por: de Leeuw, Francisca A., et al.
Publicado: (2020)

Survival in memory clinic cohort is short, even in young-onset dementia
por: Rhodius-Meester, Hanneke Frederica Maria, et al.
Publicado: (2019)

Considerations regarding a diagnosis of Alzheimer’s disease before dementia: a systematic review
por: van der Schaar, Jetske, et al.
Publicado: (2022)

Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort
por: Jutten, Roos J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c4b1ghnnjrgb531bc04fb9jn0v